Doctronic, a platform that provides 24/7 access to an AI doctor, recently announced it has raised $20 million in Series A funding.

Lightspeed Venture Partners led the funding round, which also included Tusk Ventures, Mantis VC, Union Square Ventures, Seven Stars, and angel investors such as Dr. Fei-Fei Li, Jay Desai, and Scott Belsky.

The new funding will allow Doctronic to grow its services and speed up its mission to offer more Americans instant, affordable, and personalized healthcare — both directly to consumers and through new partnerships with payers and health systems, the press release stated.

Founded by Dr. Adam Oskowitz and Matt Pavelle, Doctronic is based on the idea that generative AI can help address one of America's biggest healthcare issues, as stated in the press release: providing quality care when needed. The platform offers personalized, anonymous health advice and provides easy access to licensed doctors through video visits for as low as $39.

According to the news release, Users can access Doctronic's AI advisor anytime for free, receiving up to four possible explanations for their symptoms, a risk-based assessment, and a detailed AI-generated plan of action, including a SOAP note (Subjective, Objective, Assessment, Plan) to share with a healthcare provider. Doctronic manages more than 50,000 weekly visits, has facilitated 15 million medical conversations with over 1 million unique users. Noted on its homepage, Doctronic states it’s HIPAA compliant.

Doctronic has already started forming partnerships with payers and health systems. This fall, Doctronic will begin providing its AI-native solution to over 100,000 patients through a partnership with Safe Harbor Health.

"Doctronic is scaling at a pace that makes it clear the future of healthcare will be AI-driven," said Faraz Fatemi, Partner at Lightspeed Venture Partners, in a statement. "What sets them apart is far more than just speed or convenience, but a fundamentally unique agentic architecture that pairs collective AI intelligence with real clinical oversight.”